Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 3/2016

01-03-2016 | Review

Strategies to target drugs to gliomas and CNS metastases of solid tumors

Authors: B. Milojkovic Kerklaan, O. van Tellingen, A. D. R. Huitema, J. H. Beijnen, W. Boogerd, J. H. M. Schellens, D. Brandsma

Published in: Journal of Neurology | Issue 3/2016

Login to get access

Abstract

The treatment for central nervous system metastases of solid tumors and gliomas is limited as the blood–brain barrier (BBB) is an obstacle to systemic therapy. Here, we review the physiochemical properties of the BBB and both current and new drug strategies to penetrate brain tumors. We focus on targeting receptor- or carrier-mediated transport mechanisms over the BBB used by drug conjugates, nanoparticles, polymer-based nanocarriers, siRNA, and antibodies.
Literature
1.
2.
Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncol 4:278–299PubMedPubMedCentral
3.
Lim E, Lin NU (2014) Updates on the management of breast cancer brain metastases. Oncology (Williston Park) 28:572–578
4.
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
5.
6.
Batchelor TT et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218PubMedPubMedCentralCrossRef
7.
Tonder M et al (2014) Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. Acta Oncol 53:1436–1440PubMedCrossRef
8.
9.
Posner JB (1977) Management of central nervous system metastases. Semin Oncol 4:81–91PubMed
10.
Sperduto PW et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425PubMedPubMedCentralCrossRef
11.
Le Rhun E et al (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113:83–92PubMedCrossRef
12.
Chamberlain M et al (2014) Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-oncol
13.
Le Rhun E, Taillibert S, Chamberlain M (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 4:265–288
14.
15.
Wick W et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174PubMedPubMedCentralCrossRef
16.
Sperduto PW et al (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85:1312–1318PubMedPubMedCentralCrossRef
17.
Stupp R et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28:2712–2718PubMedCrossRef
18.
Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28:202–208PubMedCrossRef
19.
Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR (2013) Characterization of the blood–brain barrier of metastatic and primary malignant neoplasms. J Neurosurg 119:427–433PubMedPubMedCentralCrossRef
20.
Lockman PR et al (2010) Heterogeneous blood–tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664–5678PubMedPubMedCentralCrossRef
21.
22.
23.
Mathiisen TM, Lehre KP, Danbolt NC, Ottersen OP (2010) The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58:1094–1103PubMedCrossRef
24.
25.
Charest G, Sanche L, Fortin D, Mathieu D, Paquette B (2013) Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. J Neurooncol 115:365–373PubMedCrossRef
26.
Doolittle ND et al (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637–647PubMedCrossRef
27.
Stamatovic SM, Keep RF, Andjelkovic AV (2008) Brain endothelial cell–cell junctions: how to ‘open’ the blood brain barrier. Curr Neuropharmacol 6:179–192PubMedPubMedCentralCrossRef
28.
Cote J et al (2010) Selective tumor blood–brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides 44:177–185PubMedCrossRef
29.
Cuddapah VA, Turner KL, Seifert S, Sontheimer H (2013) Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3.1 and ClC-3. J Neurosci 33:1427–1440PubMedPubMedCentralCrossRef
30.
Emerich DF, Dean RL, Osborn C, Bartus RT (2001) The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood–brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 40:105–123PubMedCrossRef
31.
Zhou L et al (2014) Bradykinin regulates the expression of claudin-5 in brain microvascular endothelial cells via calcium-induced calcium release. J Neurosci Res 92:597–606PubMedCrossRef
32.
Chi OZ, Wei HM, Lu X, Weiss HR (1996) Increased blood–brain permeability with hyperosmolar mannitol increases cerebral O2 consumption and O2 supply/consumption heterogeneity. J Cereb Blood Flow Metab 16:327–333PubMedCrossRef
33.
Rodriguez A, Tatter S, Debinski W (2015) Neurosurgical techniques for disruption of the blood–brain barrier for glioblastoma treatment. Pharmaceutics 7:175–187PubMedPubMedCentralCrossRef
34.
Shin BJ, Burkhardt JK, Riina HA, Boockvar JA (2012) Superselective intra-arterial cerebral infusion of novel agents after blood–brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series. Neurosurg Clin N Am 23:323–329PubMedCrossRef
35.
Liu L-B et al (2015) Bradykinin increased the permeability of BTB via NOS/NO/ZONAB-mediating down-regulation of claudin-5 and occludin. Biochem Biophys Res Commun 464:118–125PubMedCrossRef
36.
Prados MD et al (2003) A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncology 5:96–103PubMedPubMedCentral
37.
38.
Kirson ED et al (2004) Disruption of cancer cell replication by alternating electric fields. Cancer Res 64:3288–3295PubMedCrossRef
39.
Sloan AE et al (2013) Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg 118:1202–1219PubMedCrossRef
40.
Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K (2004) Cellular mechanisms of the blood–brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 30:979–989PubMedCrossRef
41.
Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N (2005) Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24:12–20PubMedCrossRef
42.
Liu H-L, Fan C-H, Ting C-Y, Yeh C-K (2014) Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics 4:432–444PubMedPubMedCentralCrossRef
43.
Jenne JW (2015) Non-invasive transcranial brain ablation with high-intensity focused ultrasound. Front Neurol Neurosci 36:94–105PubMedCrossRef
44.
Schober R, Bettag M, Sabel M, Ulrich F, Hessel S (1993) Fine structure of zonal changes in experimental Nd:YAG laser-induced interstitial hyperthermia. Lasers Surg Med 13:234–241PubMedCrossRef
45.
Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC (2014) Stereotactic laser ablation of high-grade gliomas. Neurosurg Focus 37:E1PubMedCrossRef
46.
Golberg A, Yarmush ML (2013) Nonthermal irreversible electroporation: fundamentals, applications, and challenges. IEEE Trans Biomed Eng 60:707–714PubMedCrossRef
47.
Ellis TL et al (2011) Nonthermal irreversible electroporation for intracranial surgical applications. Laboratory investigation. J Neurosurg 114:681–688PubMedCrossRef
48.
49.
Hawkins RA, O’Kane RL, Simpson IA, Vina JR (2006) Structure of the blood–brain barrier and its role in the transport of amino acids. J Nutr 136:218S–226SPubMed
50.
Simpson IA, Carruthers A, Vannucci SJ (2007) Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 27:1766–1791PubMedPubMedCentralCrossRef
51.
Vlieghe P, Khrestchatisky M (2013) Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev 33:457–516PubMedCrossRef
52.
Deane R, Zlokovic BV (2007) Role of the blood–brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 4:191–197PubMedCrossRef
53.
Li YM, Vallera DA, Hall WA (2013) Diphtheria toxin-based targeted toxin therapy for brain tumors. J Neurooncol 114:155–164PubMedCrossRef
54.
55.
Dufes C, Al Robaian M, Somani S (2013) Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv 4:629–640PubMedCrossRef
56.
Saldana SM et al (2013) Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One 8:e73406PubMedPubMedCentralCrossRef
57.
Gaillard PJ, Visser CC, de Boer AG (2005) Targeted delivery across the blood–brain barrier. Expert Opin Drug Deliv 2:299–309PubMedCrossRef
58.
59.
60.
Tang J et al (2014) The association between blood–cerebrospinal fluid barrier dysfunction and the therapeutic effect in tuberculous meningitis patients. Eur Neurol 71:331–336PubMedCrossRef
61.
Engelhardt B, Sorokin L (2009) The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 31:497–511PubMedCrossRef
62.
Ek CJ, Habgood MD, Dziegielewska KM, Saunders NR (2003) Structural characteristics and barrier properties of the choroid plexuses in developing brain of the opossum (Monodelphis domestica). J Comp Neurol 460:451–464PubMedCrossRef
63.
Yasuda K et al (2013) Drug transporters on arachnoid barrier cells contribute to the blood–cerebrospinal fluid barrier. Drug Metab Dispos 41:923–931PubMedPubMedCentralCrossRef
64.
65.
Tachikawa M et al (2012) A clearance system for prostaglandin D2, a sleep-promoting factor, in cerebrospinal fluid: role of the blood–cerebrospinal barrier transporters. J Pharmacol Exp Ther 343:608–616PubMedCrossRef
66.
Saunders NR, Daneman R, Dziegielewska KM, Liddelow SA (2013) Transporters of the blood–brain and blood–CSF interfaces in development and in the adult. Mol Asp Med 34:742–752CrossRef
67.
Nagaraja TN et al (2005) In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res 2:5PubMedPubMedCentralCrossRef
68.
Pavan B, Paganetto G, Rossi D, Dalpiaz A (2014) Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug Discov Today 19:1563–1571PubMedCrossRef
69.
De Vries NA et al (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440–6449PubMedCrossRef
70.
Schinkel AH et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491–502PubMedCrossRef
71.
Demeule M et al (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vascul Pharmacol 38:339–348PubMedCrossRef
72.
Gazzin S et al (2008) Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood–brain interfaces. J Comp Neurol 510:497–507PubMedCrossRef
73.
Tachikawa M et al (2005) Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. J Neurochem 95:294–304PubMedCrossRef
74.
Liu X, Cheong J, Ding X, Deshmukh G (2014) Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats. Drug Metab Dispos 42:482–491PubMedCrossRef
75.
76.
Kemper EM et al (2003) Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849–2855PubMed
77.
Breedveld P, Beijnen JH, Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17–24PubMedCrossRef
78.
Lin F et al (2013) Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin Cancer Res 19:2084–2095PubMedCrossRef
79.
Böck JC, Kaufmann F, Felix R (1996) Comparison of gadolinium-DTPA and macromolecular gadolinium-DTPA-polylysine for contrast-enhanced pulmonary time-of-flight magnetic resonance angiography. Invest Radiol 31:652–657PubMedCrossRef
80.
Kornguth S et al (1990) Glioblastoma multiforme: MR imaging at 1.5 and 9.4 T after injection of polylysine-DTPA-Gd in rats. Am J Neuroradiol (AJNR) 11:313–318
81.
Zagzag D, Goldenberg M, Brem S (1989) Angiogenesis and blood–brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain–tumor model. Am J Roentgenol (AJR) 153:141–146CrossRef
82.
Awasthi R et al (2012) Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology 54:205–213PubMedCrossRef
83.
Yonemori K et al (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116:302–308PubMedCrossRef
84.
Spuch C, Ortolano S, Navarro C (2012) LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer’s disease. Front Physiol 3:269PubMedPubMedCentralCrossRef
85.
Demeule M et al (2008) Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 106:1534–1544PubMedCrossRef
86.
Thomas FC et al (2009) Uptake of ANG1005, a novel paclitaxel derivative, through the blood–brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 26:2486–2494PubMedPubMedCentralCrossRef
87.
Drappatz J et al (2013) Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 19:1567–1576PubMedCrossRef
88.
Kurzrock R et al (2012) Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther 11:308–316PubMedCrossRef
89.
Lin NU, Schwartzberg LS, Kesari S, Yardley DA, Verma S, Anders CK, Shih T, Shen Y, Miller K (2012) A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer. Cancer Res 72:1057–1065CrossRef
90.
91.
92.
Metselaar JM, Storm G (2005) Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv 2:465–476PubMedCrossRef
93.
Fukumura D, Duda DG, Munn LL, Jain RK (2010) Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17:206–225PubMedPubMedCentralCrossRef
94.
Groll AH et al (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182:274–282PubMedCrossRef
95.
96.
Birngruber T et al (2013) Cerebral open flow microperfusion: a new in vivo technique for continuous measurement of substance transport across the intact blood–brain barrier. Clin Exp Pharmacol Physiol 40:864–871PubMedCrossRef
97.
Gaillard PJ et al (2014) Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 9:e82331PubMedPubMedCentralCrossRef
98.
Milojkovic Kerklaan B et al (2013) Phase I dose escalating study of 2B3-101, glutathione pegylated liposomal doxorubicin, in patients with solid tumors and brain metastases or reccurent malignant glioma. Neuro-oncol 15, abstract 15
99.
Li Y et al (2012) A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33:3899–3908PubMedCrossRef
100.
Grover A, Hirani A, Pathak Y, Sutariya V (2014) Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer. AAPS PharmSciTech 15:1562–1568PubMedPubMedCentralCrossRef
101.
Geldenhuys W, Mbimba T, Bui T, Harrison K, Sutariya V (2011) Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 19:837–845PubMedCrossRef
102.
103.
Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12:967–977PubMedCrossRef
104.
105.
Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef
106.
Tsujiuchi T et al (2014) Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. Am J Transl Res 6:169–178PubMedPubMedCentral
107.
108.
Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR (2014) Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 35:5226–5239PubMedCrossRef
109.
Patil A, Sherbet G (2015) Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain. Cancer Lett 35:93–99CrossRef
110.
Patil R, Ljubimov AV, Gangalum PR, Ding H, Portilla-Arias J, Wagner S, Inoue S, Konda B, Rekechenetskiy A, Chesnokova A, Markman JL, Ljubimov VA, Li D, Prasad RS, Black KL, Holler E, Ljubimova J (2015) MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain. ACS Nano 9(5):5594–608. doi:10.​1021/​acsnano.​5b01872 PubMedPubMedCentralCrossRef
111.
Regina A, Demeule M, Tripathy S, Lord-Dufour S, Currie JC, Iddir M, Annabi B, Castaigne JP, Lachowicz J (2015) ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther 14(1):129–140. doi:10.​1158/​1535-7163.​MCT-14-0399 PubMedCrossRef
112.
Van den Bent MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350PubMedCrossRef
113.
Cairncross G et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedPubMedCentralCrossRef
114.
115.
Shaw EG et al (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30:3065–3070PubMedPubMedCentralCrossRef
116.
Buckner JC, Pugh SL, Shaw EG, Gilbert MR, Barger G, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary J-P, Jean Fisher B, Haro WJC, Mehta MP (2014) Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with alliance, ECOG, and SWOG. J Clin Oncol ASCO Annu Meet Abstr 32, abstract 2000
117.
Otieno MA, Baggs RB, Hayes JD, Anders MW (1997) Immunolocalization of microsomal glutathione S-transferase in rat tissues. Drug Metab Dispos 25:12–20PubMed
118.
Takeda A, Takatsuka K, Connor JR, Oku N (2001) Abnormal iron accumulation in the brain of neonatal hypotransferrinemic mice. Brain Res 7:154–161CrossRef
119.
Roberts LM et al (2008) Subcellular localization of transporters along the rat blood–brain barrier and blood–cerebral–spinal fluid barrier by in vivo biotinylation. Neuroscience 155:423–438PubMedCrossRef
120.
Redzic Z (2011) Molecular biology of the blood–brain and the blood–cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8:3PubMedPubMedCentralCrossRef
121.
Brandsma D et al (2014) Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in patients with brain metastases (BM) from solid tumors or recurrent high grade glioma. Ann Oncol 25(suppl):iv146–iv164
122.
Regina A et al (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155:185–197PubMedPubMedCentralCrossRef
123.
Pang Z et al (2011) Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Bioconjug Chem 22:1171–1180PubMedCrossRef
124.
125.
Sarkar G, Curran GL, Sarkaria JN, Lowe VJ, Jenkins RB (2014) Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. PLoS One 9:e97655PubMedPubMedCentralCrossRef
126.
Yang Y et al (2014) PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials 35:4368–4381PubMedCrossRef
127.
Dilnawaz F et al (2012) The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 33:2936–2951PubMedCrossRef
128.
Wang P, Liu Y, Shang X, Xue Y (2011) CRM197-induced blood–brain barrier permeability increase is mediated by upregulation of caveolin-1 protein. J Mol Neurosci 43:485–492PubMedCrossRef
129.
Gooding M, Malhotra M, McCarthy DJ, Godinho BM, Cryan JF, Darcy R, O’Driscoll C (2015) Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis. Eur J Pharm Sci 71:80–92. doi:10.​1016/​j.​ejps.​2015.​02.​007 PubMedCrossRef
130.
Kievit FM, Stephen ZR, Wang K, Dayringer CJ, Sham JG, Ellenbogen RG, Silber JR, Zhang M (2015) Nanoparticle mediated silencing of DNA repair sensitizes pediatric brain tumor cells to γ-irradiation. Mol Oncol 29:1071–1080CrossRef
Metadata
Title
Strategies to target drugs to gliomas and CNS metastases of solid tumors
Authors
B. Milojkovic Kerklaan
O. van Tellingen
A. D. R. Huitema
J. H. Beijnen
W. Boogerd
J. H. M. Schellens
D. Brandsma
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 3/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7919-9

Other articles of this Issue 3/2016

Journal of Neurology 3/2016 Go to the issue

Original Communication

Disrupted effective connectivity of the sensorimotor network in amyotrophic lateral sclerosis

Letter to the Editors

Two cases of multiple sclerosis manifesting after in vitro fertilization procedures

Acknowledgement

Acknowledgement to reviewers 2015

Original Communication

Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study

Letter to the Editors

MRI abnormalities found 1 year prior to symptom onset in a case of Creutzfeldt–Jakob disease

Journal club

Advances in biomarker research in multiple sclerosis